# OR5B12

## Overview
OR5B12 is a gene that encodes the protein olfactory receptor family 5 subfamily B member 12, which is part of the olfactory receptor family. This family of proteins is categorized as G-protein-coupled receptors (GPCRs), which are integral membrane proteins involved in detecting odor molecules and initiating olfactory signal transduction. The OR5B12 protein is primarily expressed in the olfactory epithelium, where it plays a crucial role in the sense of smell by binding specific odorants and activating downstream signaling pathways. The gene's expression and function have been studied in various contexts, including its potential involvement in certain diseases, highlighting its significance beyond olfactory perception (Zeneyedpour2019Neoantigens; Park2022Investigation).

## Clinical Significance
The gene OR5B12 has been implicated in various diseases and conditions through mutations and alterations in its expression. In the context of chronic obstructive pulmonary disease (COPD), coding mutations in OR5B12 have been associated with the disease, suggesting a potential role in its pathogenesis (Zeneyedpour2019Neoantigens). This association highlights the possibility of using OR5B12 mutations as biomarkers for categorizing patients for early treatment and prevention strategies in COPD.

In the realm of hematological disorders, OR5B12 has been identified as one of the downregulated genes in normal karyotype acute myeloid leukemia (NK-AML) patients with decreased platelet counts (PD-AML) compared to those with normal platelet counts (PND-AML) (Park2022Investigation). This downregulation may contribute to the pathophysiology of thrombocytopenia in NK-AML, indicating its potential as a predictive marker for distinguishing between different patient groups.

These findings underscore the clinical significance of OR5B12 in both respiratory and hematological conditions, suggesting that alterations in this gene may have broader implications for disease mechanisms and therapeutic targeting. However, further research is needed to fully elucidate the role of OR5B12 in these and potentially other conditions.


## References


[1. (Zeneyedpour2019Neoantigens) Lona Zeneyedpour, Lennard J. M. Dekker, Jenny J. M. van Sten‐van`t Hoff, Peter C. Burgers, Nick H. T. ten Hacken, and Theo M. Luider. Neoantigens in chronic obstructive pulmonary disease and lung cancer: a point of view. PROTEOMICS – Clinical Applications, February 2019. URL: http://dx.doi.org/10.1002/prca.201800093, doi:10.1002/prca.201800093. This article has 10 citations.](https://doi.org/10.1002/prca.201800093)

[2. (Park2022Investigation) Chang-Hun Park and Jae Won Yun. Investigation of biomarkers associated with low platelet counts in normal karyotype acute myeloid leukemia. International Journal of Molecular Sciences, 23(14):7772, July 2022. URL: http://dx.doi.org/10.3390/ijms23147772, doi:10.3390/ijms23147772. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms23147772)